Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA349615
Max Phase: Preclinical
Molecular Formula: C13H11IN4O
Molecular Weight: 366.16
Molecule Type: Small molecule
Associated Items:
ID: ALA349615
Max Phase: Preclinical
Molecular Formula: C13H11IN4O
Molecular Weight: 366.16
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1nc(O)c2[nH]cc(Cc3ccc(I)cc3)c2n1
Standard InChI: InChI=1S/C13H11IN4O/c14-9-3-1-7(2-4-9)5-8-6-16-11-10(8)17-13(15)18-12(11)19/h1-4,6,16H,5H2,(H3,15,17,18,19)
Standard InChI Key: GFFQSWANLMANPJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 366.16 | Molecular Weight (Monoisotopic): 365.9978 | AlogP: 2.44 | #Rotatable Bonds: 2 |
Polar Surface Area: 87.82 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.00 | CX Basic pKa: 1.85 | CX LogP: 3.70 | CX LogD: 3.70 |
Aromatic Rings: 3 | Heavy Atoms: 19 | QED Weighted: 0.61 | Np Likeness Score: -0.46 |
1. Montgomery JA, Niwas S, Rose JD, Secrist JA, Babu YS, Bugg CE, Erion MD, Guida WC, Ealick SE.. (1993) Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine., 36 (1): [PMID:8421291] [10.1021/jm00053a008] |
Source(1):